BioCryst Pharmaceuticals Inc. took an inventive tack to raise $30 million this week by monetizing payments from licensee Shionogi & Co. Ltd., of Osaka, Japan, for peramivir (Rapiacta), a neuraminidase inhibitor for the treatment of influenza.